Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals is a U.S.-based biopharmaceutical company focused on endocrine diseases and endocrine-related tumors. It develops small-molecule therapies that target GPCR biology, with PALSONIFY (paltusotine) as its first approved product and a broader pipeline spanning acromegaly, Cushing syndrome, congenital adrenal hyperplasia, neuroendocrine tumors and other endocrine disorders.

−6 664,1 %

86,0 %

−6 046,2 %

+640,7 %

12.32

12.30

— Crinetics Pharmaceuticals, Inc.
%
Commercial endocrine therapy20% Approved and marketed therapy for acromegaly, anchored by PALSONIFY.
Late-stage clinical candidates45% Programs in Phase 2/3 and other advanced development stages, including paltusotine and atumelnant.
Oncology and radiopharmaceutical pipeline15% SST2-targeted and oncology-adjacent programs such as CRN09682 and related discovery assets.
Discovery-stage endocrine programs20% Earlier research programs across endocrine and metabolic diseases.

Crinetics sells primarily to specialty physicians and healthcare systems treating rare endocrine disorders, with...

  • Specialty physiciansprimary

    Endocrinologists and rare-disease specialists prescribing PALSONIFY and future endocrine therapies.

  • Payers and reimbursement gatekeepersprimary

    Commercial and government payers that influence access, formulary placement and patient uptake.

  • International license partnerssecondary

    Partners such as Sanwa in Japan that develop and commercialize paltusotine locally.

  • Patients with rare endocrine diseasesprimary

    Adults with acromegaly and other endocrine disorders who benefit from chronic oral therapy.

  • Oncology research and development partnersemerging

    Collaborators and future partners for SST2-expressing tumors and radiopharmaceutical programs.

Crinetics is headquartered in the United States and currently commercializes PALSONIFY in the U.S...

  • •United States is the core commercial market for PALSONIFY
  • •Europe is an expansion focus through EMA review of PALSONIFY
  • •Japan is covered through the Sanwa license arrangement
  • •Drug substance is synthesized in India for the supply chain
  • •Bioavailability optimization occurs in Portugal; finished product in the U.S.

Crinetics is transitioning from a development-stage biotech into a commercial rare-disease company while continuing to...

01
Commercialize PALSONIFY in the U.S.short-term

The approved product is the first source of product revenue and validates the platform.

02
Expand paltusotine into new indications and regionsmedium-term

Additional indications and geographies can extend the product lifecycle and broaden the addressable market.

03
Advance the broader endocrine pipelinemedium-term

A diversified pipeline reduces dependence on a single product and supports long-term growth.

Crinetics remains exposed to the execution risk of a newly commercialized rare-disease product, including physician...

high

Limited commercialization track record

The company has FDA approval but has not yet proven sustained commercial execution for PALSONIFY.

Scope
U.S. launch and specialty market uptake
Materiality
high
high

Clinical development failure

Pipeline value depends on positive trial outcomes and regulatory approvals across multiple indications.

Scope
Paltusotine, atumelnant, CRN09682 and discovery programs
Materiality
high
high

Third-party manufacturing dependence

The company does not own commercial manufacturing facilities and relies on CMOs and suppliers.

Scope
Drug substance in India, optimization in Portugal, finished product in the U.S.
Materiality
high
medium

Capital requirements and dilution

Ongoing R&D, launch costs and clinical programs can outpace internally generated cash flow.

Scope
Future financings if product revenue ramps slowly
Materiality
high
medium

Foreign regulatory and reimbursement exposure

International expansion depends on approvals, pricing and reimbursement decisions outside the U.S.

Scope
Europe and Japan
Materiality
medium
Revenue recognition for licenses and collaborations
Can create uneven quarterly revenue and deferred revenue balances
Initial product revenue recognition
May affect reported sales timing and gross-to-net deductions
Accrued research and development expenses
Affects operating expense and period-to-period comparability
Stock-based compensation
Can materially widen reported net losses
Lease and other estimates
Affects liabilities and operating cost presentation

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

SCYNEXIS INC

SCYX · Pharmaceutical Preparations

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

Rein Therapeutics, Inc.

RNTX · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

: 28.4.2026